Back to top

medical-devices: Archive

Zacks Equity Research

Merit Medical Expands GI Portfolio With $22M C2 CryoBalloon Acquisition

MMSI is set to acquire C2 CryoBalloon from Pentax for $22M, strengthening its GI portfolio. Despite near-term dilution, the deal positions Merit for long-term growth in gastroenterology.

MASINegative Net Change MMSINegative Net Change DRIONegative Net Change NDRAPositive Net Change

Zacks Equity Research

GEHC Stock Up Following New Launch to Streamline Perinatal Workflow

GE HealthCare unveils CareIntellect for Perinatal, a SaaS tool aimed at improving maternal and fetal care delivery.

RMDPositive Net Change HCANegative Net Change GEHCPositive Net Change SOLVPositive Net Change

Zacks Equity Research

Reasons to Hold Veeva Systems Stock in Your Portfolio for Now

VEEV's strong Q2, expanding AI strategy and major life sciences partnerships fuel growth despite rising costs.

MASINegative Net Change MMSINegative Net Change WSTNegative Net Change VEEVPositive Net Change

Zacks Equity Research

Abbott's Q3 Earnings Meet Estimates, Revenues Up Y/Y, Stock Climbs

ABT's Q3 earnings meet expectations as revenues climb 6.9% year over year, driven by double-digit gains in Medical Devices.

ABTPositive Net Change PODDPositive Net Change PAHCNegative Net Change VCYTNegative Net Change

Zacks Equity Research

Labcorp Gears Up to Report Q3 Earnings: What's in Store for the Stock?

LH is poised for Q3 growth, with revenue and EPS estimates pointing higher as diagnostics and biopharma units deliver strong performances.

LHNegative Net Change IDXXPositive Net Change ANIPNegative Net Change EXASPositive Net Change

Indrajit Bandyopadhyay

Can Ion Emerge as ISRG's Vehicle to Tap Ambulatory Care Growth?

Intuitive Surgical's Ion platform gains traction in ambulatory centers, driving 52% growth as outpatient lung diagnostics accelerate.

BSXNegative Net Change BDXPositive Net Change ISRGNegative Net Change

Zacks Equity Research

Reasons to Retain West Pharmaceutical Stock in Your Portfolio for Now

WST's growth prospects remain strong, fueled by GLP-1 demand and high-value products, though tariffs and execution risks weigh on margins.

CAHPositive Net Change MASINegative Net Change MMSINegative Net Change WSTNegative Net Change

Urmimala Biswas

NVDA & PLTR Driving AI in Health: Top Health IT Stocks for Q3 Earnings

NVDA and PLTR drive AI integration across healthcare, fueling optimism for Omnicell and Tempus AI's Q3 performance.

NVDANegative Net Change OMCLPositive Net Change ORCLPositive Net Change PLTRPositive Net Change TEMPositive Net Change

Debanjana Dey

Hims & Hers Gains 3.8% in 3 Months: Time to Hold the Stock or Sell?

HIMS expands into men's health and hormones, but rising costs and regulatory hurdles threaten its momentum.

TDOCPositive Net Change AMWLNegative Net Change HIMSPositive Net Change

Zacks Equity Research

STXS Partners With CardioFocus to Boost Robotic Pulsed Field Ablation

Stereotaxis partners with CardioFocus to commercialize the first robotic Pulsed Field Ablation system, aiming to revolutionize cardiac arrhythmia treatment.

MASINegative Net Change MMSINegative Net Change STXSPositive Net Change WSTNegative Net Change

Zacks Equity Research

Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings

DGX is poised for solid Q3 2025 results, backed by strong DIS growth, strategic M&A and robust test demand across key health segments.

DGXPositive Net Change IDXXPositive Net Change ANIPNegative Net Change EXASPositive Net Change

Moumi Mondal

HOLX's Enhanced Fibroid Treatment Portfolio Powers GYN Surgical Growth

Hologic's GYN Surgical segment gains momentum internationally as expanded fibroid treatments support growth.

JNJNegative Net Change MDTPositive Net Change HOLXPositive Net Change

Indrajit Bandyopadhyay

Can ISRG Continue Its Strong Growth Amid Tariff & Rare Earth Woes?

ISRG's growth momentum faces pressure as tariffs and China's rare earth export curbs threaten margins and supply stability.

SYKPositive Net Change ISRGNegative Net Change GMEDPositive Net Change

Zacks Equity Research

New Strong Sell Stocks for Oct. 14th

AR, BTCS and ATOS have been added to the Zacks Rank #5 (Strong Sell) List on October 14, 2025.

ATOSPositive Net Change ARPositive Net Change BTCSPositive Net Change

Zacks Equity Research

BD Stock Down Despite Making Progress in the Treatment of PAD Lesions

BDX advances PAD care with first patient enrolled in the XTRACT Registry using its dual-action Rotarex system.

BDXPositive Net Change RMDPositive Net Change MASINegative Net Change SOLVPositive Net Change

Zacks Equity Research

INSP Shares Down Despite Strong Clinical Data From Inspire V Trials

Inspire Medical's Inspire V system shows strong safety, faster surgeries, and higher patient adherence in new trials.

MASINegative Net Change MMSINegative Net Change WSTNegative Net Change INSPNegative Net Change

Moumi Mondal

CVS' Aetna Wins Big on 2026 MA Star Ratings: How to Play the Stock?

CVS' Aetna shines in 2026 Medicare Star Ratings, with more than 81% of members in four-star plans, fueling a 73.5% YTD stock surge and strong investor momentum.

UNHNegative Net Change HUMPositive Net Change CVSNegative Net Change

Zacks Equity Research

Pulse Biosciences Unveils Promising First-in-Human Data for nPulse

PLSE unveils strong first-in-human data for its nPulse Cardiac Surgical System, showcasing safety, speed, and durable AF treatment potential.

EWNegative Net Change MASINegative Net Change PLSENegative Net Change NDRAPositive Net Change

Zacks Equity Research

BD Stock Down Despite Tie-Up to Boost Single-Cell Sequencing Workflow

BDX teams with Opentrons to automate single-cell sequencing, advancing its multiomics and biosciences strategy.

BDXPositive Net Change RMDPositive Net Change MASINegative Net Change SOLVPositive Net Change

Urmimala Biswas

3 Medical Service Industry Stocks Poised to Counter Workforce Issues

Here are three resilient medical services stocks, Labcorp, Charles River Laboratories and Teladoc, that are poised to outperform amid staffing shortages and digital healthcare growth.

LHNegative Net Change CRLPositive Net Change TDOCPositive Net Change

Zacks Equity Research

Here's Why You Should Retain PacBio Stock in Your Portfolio for Now

PACB's Q2 beat, expanding Revio and Vega systems and growing clinical traction highlight its innovation-led recovery despite longer purchasing cycles.

MASINegative Net Change MMSINegative Net Change WSTNegative Net Change PACBPositive Net Change

Zacks Equity Research

GE Healthcare Partners With Erasmus to Advance Precision Cancer Care

GEHC's collaboration with Erasmus MC aims to advance precision oncology using next-gen total body PET/CT and AI imaging innovations.

MASINegative Net Change MMSINegative Net Change WSTNegative Net Change GEHCPositive Net Change